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Background: To investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and
carcinoembryonic antigen (CEA)] and clinicopathological parameters and patient outcomes in breast cancer.
Materials and methods: A total of 740 patients with stages I–III breast cancer had preoperative CA 15-3 and
CEA concentrations measured. Univariate and multivariate analyses were used to investigate associations
between marker concentration and clinicopathological parameters and patient outcomes.
Results: Among 740 patients, elevated preoperative levels of CA 15-3 and CEA were identified in 92 (12.4%)
and 79 (10.7%) patients, respectively. Tumor size (>5 cm), node metastases (‡4), and advanced stage (‡III) were
associated with higher preoperative levels. Elevated CA 15-3 and CEA levels were associated with poor disease-free
survival (DFS, P = 0.0014, P = 0.0001, respectively) and overall survival (OS, P = 0.018, P = 0.015) even in
stage-matched analysis. Patients with normal levels of both CA 15-3 and CEA showed better DFS and OS than those
with elevated group. In multivariate analysis, age (<35 years), tumor size (>2 cm), node metastases, estrogen receptor
expression, and elevated CA 15-3 and CEA preoperative values were independent prognostic factors for DFS.
Conclusion: High preoperative CA 15-3 and CEA levels may reflect tumor burden and are associated with advanced
disease and poor outcome. Measuring preoperative levels of CA 15-3 and CEA can be helpful for predicting
outcomes.
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introduction
Axillary lymph node status has been the most important
prognostic factor for primary breast cancer; tumor size,
histologic grade (HG), and hormone receptors status are also
traditional prognostic factors. In addition, circulating tumor
markers, such as cancer antigen 15-3 (CA 15-3) and
carcinoembryonic antigen (CEA), have been evaluated for use
as predictive parameters in patient outcome and treatment
response. Although its usefulness remains uncertain and
American Society of Clinical Oncology guidelines do not
recommend its use for follow-up [1], measurement of
circulating CA 15-3 and CEA levels is widely used for
surveillance purposes in clinical field. It is a fast, noninvasive,
reproducible, and quantitative serum test.
CA 15-3 is the product of MUC-1 gene, and mucins are
aberrantly overexpressed in many adenocarcinomas in an
underglycosylated form and then shed into the circulation [2,
3]. Therefore, higher level of CA 15-3 may be associated with
larger burden of occult disease and poor outcome. There have
been many reports showing worse prognosis in patients with
high concentration of CA 15-3 [4–7], and CA 15-3 has been
shown to be an independent predictor of first recurrence as well
as a powerful prognostic indicator in patients with advanced
breast cancer [8].
Although the value of CEA has greatly reduced with arising
the value of CA 15-3 in breast cancer field, CEA is one of the
first tumor markers and there have been many reports related
to negative prognostic effect [9, 10]. Several authors have
shown that an increase or a decrease in the CEA level may
reflect the status of disease progression or regression [11, 12].
CEA may be useful in the postoperative follow-up of the breast
cancer patients for an early diagnosis of recurrence [13–15] and
for monitoring response to treatment [16, 17].
In the present study, we retrospectively evaluated the
relationship between the level of the markers and
clinicopathological parameters and then the ability of CEA and
CA 15-3 serum levels in predicting breast cancer outcome using
univariate and multivariate analyses.
materials and methods
patients
A total of 740 patients treated at Yonsei University Severance Hospital
from April 1999 to December 2003 with breast cancer had their
preoperative CA 15-3 and CEA concentrations measured. All tumors
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were invasive cancers with stages I–III, and the median age of patients
was 47 years (range 20–88 years).
Patients were treated with either modified radical mastectomy or
quadrantectomy and axillary lymph node dissection with local
radiotherapy. After completion of surgery, radiotherapy and appropriate
adjuvant chemotherapy or hormone therapy was not altered according to
the marker levels but was administered as indicated based on the
international guidelines. General clinicopathological parameters such as
tumor size, axillary node involvement, HG, estrogen receptor (ER),
progesterone receptor, HER2 expression, and age are summarized in
Table 1. Staging was based on 6th American Joint Committee on Cancer
criteria. Clinical follow-up included history taking, physical examination,
and laboratory tests, including CEA and CA 15-3, liver function test,
complete blood count, chest radiography, abdominal and breast
ultrasonography, mammography, and bone scan every 6–12 months, for
detection of local or distant relapse. Additional computed tomography and
radiography were obtained as necessary.
marker analysis
Serum tumor markers were determined by automated immunoanalyzer
systems using chemiluminiscent immunoassay for CEA (ADVIA Centaur,
Bayer HealthCare LLC Diagnostic Division, NY) and CA 15-3 (VITROS
Table 1. General characteristics of study population
Characteristics (N) n %
Age (740)
£35 years 75 10.1
>35 years 665 89.9
Tumor size (740)
T1 411 55.5
T2 308 41.6
‡T3 21 2.8
Nodal status (740)
N0 431 58.2
N1 183 24.7
N2 84 11.4
N3 42 5.7
TNM stage (740)
I 284 38.4
II 329 44.4
III 127 17.2
HG (628)
I 123 19.6
II 316 50.3
III 189 30.1
ER (710)
Negative 267 37.6
Positive 443 62.4
PR (711)
Negative 387 54.4
Positive 324 45.6
HER2 (699)
Negative 434 62.1
Positive 265 37.9
CA 15-3 (740)
£20.11 648 87.6
>20.11 92 12.4
CEA (740)
£3.88 661 89.3
>3.88 79 10.7
TNM, tumor–node–metastasis; HG, histologic grade; ER, estrogen receptor;
PR, progesterone receptor; CA 15-3, cancer antigen 15-3; CEA,
carcinoembryonic antigen.
Table 3. Adjuvant treatment according to tumor markers levels
CA 15-3 CEA
Normal
(%)
Elevated
(%)
P value Normal
(%)
Elevated
(%)
P value
Chemotherapy
Done 427 (66) 66 (72) 0.29 436 (66) 54 (68) 0.71
No 221 (34) 26 (28) 225 (34) 25 (32)
Endocrine Tx
Done 509 (79) 76 (83) 0.41 527 (80) 58 (73) 0.19
No 139 (21) 16 (17) 134 (20) 21 (27)
Radiation Tx
Done 290 (45) 44 (48) 0.58 297 (45) 37 (46) 0.81
No 358 (55) 48 (52) 364 (55) 42 (54)
CA 15-3, cancer antigen 15-3; CEA, carcinoembryonic antigen; Tx,
treatment.
Table 2. Correlation between serum CA 15-3 and CEA level and
clinicopathological factors
CA 15-3 CEA
Mean SD P Mean SD P
Age
£35 years 13.16 6.37 0.896 1.88 2.31 0.209
>35 years 13.32 10.48 2.47 3.95
Tumor size
T1 12.77 10.08 <0.001 2.29 4.10 <0.001
T2 13.24 7.45 2.28 2.51
‡T3 24.78 26.88 6.71 8.84
Nodal status
N0 12.52 9.84 0.003 2.38 4.01 0.041
NI 13.16 7.88 1.94 1.35
N2 16.23 11.44 3.24 6.05
N3 16.66 16.75 3.16 3.47
TNM stage
I 12.37 10.60 0.001 2.29 4.17 0.037
II 13.01 8.00 2.21 2.66
III 16.37 13.38 3.22 5.32
HG
I 12.01 5.24 0.317 1.93 1.22 0.303
II 13.30 8.80 2.39 3.45
III 13.03 8.16 2.62 5.42
ER
Negative 12.71 8.24 0.284 2.53 4.85 0.418
Positive 13.50 10.07 2.30 2.86
PR
Negative 13.31 9.52 0.722 2.48 4.17 0.472
Positive 13.05 9.31 2.27 3.12
HER2
Negative 13.39 10.43 0.509 2.37 4.30 0.789
Positive 12.90 7.67 2.45 2.66
CA 15-3, cancer antigen 15-3; CEA, carcinoembryonic antigen; SD,
standard deviation; TNM, tumor–node–metastasis; HG, histologic grade;
ER, estrogen receptor; PR, progesterone receptor.
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ECi Immunodiagnostic System, Ortho-Clinical Diagnostics, Inc., NY).
Range of normality was determined by mean 6 2 standard deviations
(SDs) of the marker distribution in healthy females tested in an annual
screening program.
statistics
The difference between proportions was evaluated by the chi-square test.
Univariate survival curves for disease-free survival (DFS) and death were
estimated using the Kaplan–Meier method; group differences in survival
time were tested by the log-rank test. Multivariate Cox regression analysis
was carried out to compare and identify independent prognostic factors
for DFS and death and to calculate hazard ratios. All significant parameters
in univariate analyses were entered into a multivariate model and excluded
for P value >0.05. SPSS for Windows (version 10.0) was used for all
statistical analyses.
results
Median follow-up was 37.2 months (mean 38.7, range 1–84
months). Recurrence occurred in 91 patients (first relapse:
local recurrence alone n = 19, distant metastasis alone n = 47,
both local and systemic recurrences n = 25). There were
35 deaths, including one nonbreast cancer death.
The mean 6 SD of CA 15-3 and CEA in healthy individuals
were 11.45 6 4.33 and 1.42 6 1.23, respectively. To define
cut-off values, we chose the 95 percentile of healthy
individuals and the calculated upper limit of CA 15-3 and
CEA were 20.11 U/l and 3.88 ng/ml, respectively.
Patient demographics are listed in Table 1. Median
preoperative CEA and CA 15-3 levels were 1.66 ng/ml (range
0.19–34.37) and 10.6 U/ml (range 2.5–87.5), respectively.
Elevated CA 15-3 and CEA levels were identified in 92 (12.4%)
and 79 (10.7%) patients, respectively.
As shown in Table 2, both CA 15-3 and CEA were correlated
with larger tumor size (>5 cm) and greater lymph node
metastases (‡4). Age, HG, hormone receptor status, and
HER2 status, however, were not associated with preoperative
levels of tumor markers (Table 2).
Adjuvant treatments given after surgery were summarized
in Table 3. Because adjuvant treatment was determined not
by the tumor marker levels but by the international guidelines,
Figure 1. Survival curves according to preoperative cancer antigen 15-3 levels. Disease-free survival (A) and overall survival (B). Bold line represents patients
with normal level and dotted line represents patients with elevated levels.
Figure 2. Survival curves according to preoperative carcinoembryonic antigen levels. Disease-free survival (A) and overall survival (B). Bold line represents
patients with normal level and dotted line represents patients with elevated levels.
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there was no difference between the normal and the elevated
groups (Table 3).
Elevated CA 15-3 and CEA values were associated with poor
DFS (P = 0.0014 and P = 0.0001, respectively) and also with
overall survival (OS) (P = 0.018 and P = 0.015, respectively,
Figures 1 and 2).
In tumor stage-matched analysis, elevated CA 15-3 group
showed significantly poorer DFS (P = 0.005) and marginally
poor OS (P = 0.06) in stage III (Figure 3). In terms of CEA,
significantly poorer DFS in stages II and III (P = 0.026 and
P = 0.007, respectively) and marginally poor OS in stage II were
seen (P = 0.06) (Figure 4).
Nineteen patients had elevated levels of both CA 15-3 and
CEA, 133 showed elevated level of either CA 15-3 or CEA, and
588 were normal in both markers. Patients with normal levels
of both markers showed significantly better DFS and OS. Either
one marker elevated group showed a trend of better DFS and
OS than the group with both markers elevated, but not
statistically significant (Figure 5).
Young age (<35 years), larger tumor size (>2 cm), axillary
node metastases, and negative ER expression were also
significant prognostic factors (data not shown). Of these
prognostic factors, preoperative values of CA 15-3 and CEA
were entered into the Cox’s multivariate analysis. Young age
(<35 years), larger tumor size (>2 cm), axillary node
metastases, negative ER expression, and elevated preoperative
values of CA 15-3 and CEA were independent prognostic
factors in DFS and distant relapse-free survival; however,
patient age, elevated CA 15-3, and CEA were not statistically
significant in OS (Table 4).
discussion
In addition to traditional prognostic factors, such as axillary
lymph node status, tumor size, HG, hormone receptor
expression, and HER2 expression status, multigene assay [18]
and gene expression profiling [19, 20] have been recently
spotlighted. All these factors require tissue samples. Progressive
size reduction of detected tumor can make it difficult to obtain
samples. On the other hand, serum is easily accessible and
soluble circulating tumor markers, if found to be accurate
prognostic factors, would be ideal candidates for predicting
outcome and monitoring treatment course [21]. Measuring
markers is simple, objective, reproducible, and cost-effective,
and serum CA 15-3 and CEA have been the most frequently
investigated tumor markers in breast cancer. Due to low
Figure 3. Tumor stage-matched survival curves according to cancer antigen 15-3 levels. Disease-free survival curves of stages II and III (A and B) and overall
survival curves of stages II and III (C and D). Bold line represents patients with normal level and dotted line represents patients with elevated levels.
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sensitivity and specificity, both CA 15-3 and CEA have no
value for early detection of primary breast cancer. They can,
however, be useful in predicting prognosis, monitoring
treatment response, and surveillance.
Previous studies report variable results on the prognostic
value of CA 15-3 and CEA; small sample size, short follow-up,
and variable cut-off values contribute to the inconsistency.
Duffy et al. [22] reported that a cut-off value of CA 15-3 might
Figure 4. Tumor stage-matched survival curves according to carcinoembryonic antigen levels. Disease-free survival curves of stages II and III (A and B) and
overall survival curves of stages II and III (C and D). Bold line represents patients with normal level and dotted line represents patients with elevated levels.
Figure 5. Survival curves by combination of both levels of preoperative cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) concentrations.
Disease-free survival (A) and overall survival (B). Bold line represents patients with normal levels in both CA 15-3 and CEA, dotted line represents patients
with elevated level in either CA 15-3 or CEA, and chain line represents patients with elevated levels in both CA 15-3 and CEA.
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influence both the result and prognostic impact. We therefore
used reference values of CEA and CA 15-3 measured from
healthy women who had an annual health screening at
Severance Health Promotion Center. We determined the
normal range by mean 6 2 SDs of marker distribution in this
population and defined cut-off values by the 95 percentile
(20.11 U/ml for CA 15-3 and 3.88 ng/ml for CEA). Among 740
patients, 92 (12.4%) and 79 (10.7%) patients had levels greater
than the cut-off values for CA 15-3 and CEA, respectively
(Table 1).
As shown in Table 2 and other reports [1, 6, 8, 23], serum
levels of both CA 15-3 and CEA were associated with host
tumor burden such as larger tumor size (>5 cm), more lymph
node metastases (‡4), and advanced stage, but were not
associated with HG, hormonal receptor status, and HER2
status. Since CA 15-3 and CEA are directly associated with
host tumor burden and presence of serum tumor associated
antigens at diagnosis indicates vascularization of the tumor
with possibility of micrometastases [24], preoperative levels of
serum tumor markers could be related to poor outcome.
Taken together with other reports [4–7, 10, 22, 23, 25, 26], the
current study showed that elevated values of CA 15-3 or CEA
were associated with poor DFS (P = 0.0014 and P = 0.0001,
respectively) and poor OS (P = 0.018 and P = 0.015,
respectively). These results are further supported by the tumor
stage-matched analysis (Figures 3 and 4) and multivariate
analysis (Table 4). Despite some controversies, both CA 15-3
and CEA levels could provide independent prognostic
information to be taken together with conventional markers
measured in tumor tissues [27]. Furthermore, Duffy [28]
reported that preoperative concentrations could be combined
with existing prognostic factors for adjuvant therapy selection.
Although study sizes were small, several studies evaluating
early treatment based exclusively on increasing marker
concentrations showed improved prognosis compared with
controls [29–33]. Therefore, breast cancers with elevated
CA 15-3 or CEA could be in consideration for determining
adjuvant treatments.
As shown in Figure 5, with the combination of both marker
levels, the prognostic value is further intensified; patients with
both markers in normal level showed significantly better DFS
and OS than those with either one or both markers elevated.
This result indicates that patients showing elevated levels of
both C15-3 and CEA could be included in high-risk group for
recurrence. On the basis of the reports using preoperative CA
15-3 and CEA levels in determining adjuvant treatment [29–33]
and results shown in Figure 5, breast cancer patients with
elevated levels of both CA 15-3 and CEA should be in
consideration of early or new combination of adjuvant
treatments.
In conclusion, elevated preoperative CA 15-3 and CEA levels
are directly related to tumor burden and are independent
prognostic factors for breast cancer. Even in stage-matched
analysis and multivariate analysis, both markers showed
significant prognostic value. Therefore, both markers could be
considered for clinical use such as predicting patient outcome
and determining adjuvant treatment for better outcome.
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Table 4. Cox proportional hazards regression analysis according to age, stage, hormone receptor status, and serum markers
DFS DRFS OS
RR CI P RR CI P RR CI P
Age
<35 years
‡35 years 0.4008a 0.2140–0.7508 0.0043 0.3413a 0.1801–0.6471 0.0010 1.0939 0.3273–3.6562 0.8841
Tumor size
£2 cm
>2 cm 3.2468a 1.7518–6.0177 0.0002 3.3169a 1.7125–6.4245 0.0004 3.6533a 1.3345–10.0014 0.0117
Node
Negative
Positive 2.9665a 1.6796–5.2395 0.0002 3.2277a 1.7486–5.9576 0.0002 3.0669a 1.2631–7.4466 0.0133
ER
Negative
Positive 0.4508a 0.2710–0.7499 0.0022 0.4305a 0.2504–0.7400 0.0023 0.1994a 0.0827–0.4810 0.0003
CA 15-3
Normal
Elevated 2.0944a 1.1768–3.7274 0.0120 2.1110a 1.1333–3.9320 0.0186 2.0924 0.8758–4.9991 0.0966
CEA
Normal
Elevated 2.5640a 1.4097–4.6635 0.0020 2.0557a 1.0556–4.0033 0.0341 1.9539 0.7747–4.9280 0.1559
aSignificantly different from reference group.
DFS, disease-free survival; DRFS, distant relapse-free survival; OS, overall survival; RR, risk ratio; CI, confidence interval; ER, estrogen receptor; CA 15-3,
cancer antigen 15-3; CEA, carcinoembryonic antigen.
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